A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV

Running, not enrolling · Phase 1

Conditions studied: HIV-1-infection

In brief

This is a phase 1, first-in-human (FIH) trial for two vaccines, DV700P-RNA and DV701B1.1-RNA. This means it is the first time these study products are being tested in people. The purpose of this study is to see if the study products are safe, if people are able to take them without becoming too uncomfortable, and how a person's immune system responds to them (a person's immune system protects them from infections and disease). Forty-five volunteers without HIV and in overall good health, aged 18 to 55 years, will be enrolled and be in this study for about 16 months (about 12 visits), Study procedures will include blood draws, injections, and the collection of white blood cells and cells from their lymph nodes.

Key facts

Study ID

NCT06919016

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

45

Starts

2025-08-06

Expected to finish

2027-03-25

Last updated by the study team

2025-12-16

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Understands the study and agrees to complete the consent process.
• Can attend all clinic visits until the end of the study.
• Agrees to follow all study procedures.
• Will not join another study with experimental treatments during this trial, unless approved by both study sponsors.
• Generally healthy according to the study doctor.
• Physical exam and lab results show no major issues that could affect safety or study results.
• Agrees to discuss HIV risk and prevention.
• Hemoglobin levels: at least 11.0 g/dL for women and 13.0 g/dL for men.
• White blood cell count between 2,500 to 12,000/mm³ (higher levels okay if health is otherwise good and approved).
• Platelet count between 125,000 to 550,000/mm³.
• ALT enzyme level less than 2.5 times the upper limit of normal.
• Serum creatinine level within 1.1 times the upper limit of normal.
• Serum calcium level at least 8.5 mg/dL.
• Blood pressure within acceptable range (systolic 90-140 mmHg, diastolic 50-90 mmHg), with average below 140/90 mmHg and no single reading over 160/100 mmHg.
• Negative HIV test.
• Negative for Hepatitis C.
• Negative for Hepatitis B.
• Women who can become pregnant must use effective contraception from 21 days before joining the study until 8 weeks after the last vaccination and must have a negative pregnancy test on enrollment day.
• Women of pregnancy potential must agree not to seek pregnancy through methods like IVF from 21 days before joining the study until 8 weeks after the last vaccination.

You may not qualify if…

• Breastfeeding or pregnant.
• Body mass index (BMI) of 40 or higher, unless in good health and approved.
• Diabetes, unless it is well-controlled Type 2 diabetes or gestational diabetes.
• Previous or current investigational HIV vaccine recipients (placebo recipients are allowed).
• Received non-HIV investigational vaccines within the last year, unless they are now licensed or authorized.
• Immunodeficiency or medications that impair immune response, such as high-dose steroids.
• Received blood products or immunoglobulin within 16 weeks before enrollment.
• Received certain vaccines within the last 4 weeks before enrollment.
• Received other vaccines within 14 days before enrollment.
• History of myocarditis or pericarditis.
• Started allergy immunotherapy in the past year (unless stable and approved).
• Taken investigational research agents recently.
• Serious allergic reactions to any mRNA vaccine or drugs containing polyethylene glycol.
• History of hereditary or acquired angioedema.
• Any episode of hives (urticaria) within the past year.
• Chronic hives (urticaria).
• Hives previously caused by immunization.
• Bleeding disorder that would make study procedures unsafe.
• Seizures or use of seizure medications in the past 3 years.
• Absence of spleen or non-functional spleen.
• Active duty and reserve US military personnel.
• Any other significant condition that could affect safety or participation, including substance use, psychiatric disorders, recent suicide attempts, or cancer with potential for recurrence.
• Asthma that requires frequent or high-dose medication, recent emergency care, or multiple daily medications.
• History of certain immune-mediated conditions (mild, localized conditions may be okay).
• Allergy to local anesthetics like Novocaine or Lidocaine.

Where it is running

• University of Alabama Medical Center (Site ID: 31788) — Birmingham, Alabama, United States
• The Hope Clinic of the Emory Vaccine Center CRS (Site ID: 31440) — Decatur, Georgia, United States
• Brigham and Women's Hospital (Site ID: 30007) — Boston, Massachusetts, United States
• Columbia P&S CRS (Site ID: 30329) — New York, New York, United States
• University of Rochester Medical Center (Site ID: 31467) — Rochester, New York, United States
• University of Pittsburgh (Site ID: 1001) — Pittsburgh, Pennsylvania, United States
• Vanderbilt University Medical Center (Site ID: 30352) — Nashville, Tennessee, United States
• Seattle Vaccine and Prevention CRS (Site ID: 30331) — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.